Brief: Rigel Announces Availability Of Rezlidhia™ (Olutasidenib) In The U.S. For The Treatment Of Adult Patients With Relapsed Or Refractory Acute Myeloid Leukemia With A Susceptible Idh1 Mutation
22/12/2022 13:20
Dec 22 (Reuters) - Rigel Pharmaceuticals Inc RIGL.O :
* RIGEL ANNOUNCES AVAILABILITY OF REZLIDHIA™ (OLUTASIDENIB)
IN THE
U.S. FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR
REFRACTORY ACUTE MYELOID LEUKEMIA WITH A SUSCEPTIBLE IDH1
MUTATION
Source text for Eikon: ID:nPn5FJtFPa
Further company coverage: RIGL.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Rigel Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rigel Pharmaceuticals Q2 revenue rises on strong product demand
Brief: Rigel Pharmaceuticals - Appoints Alison L. Hannah As Executive Vice President And Chief Medical Officer Effective July 1, 2026 - SEC Filing
Brief: Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)